Culture Biosciences
Enabler → Bioprocess Optimisation; Series C
San Francisco, California
Your bioreactor lab, in the cloud.
Culture Biosciences is on a mission to revolutionise bioprocess development with a combination of hardware and software tools, turning biomanufacturing into a remotely operable process, where data can be easily accessed and analysed. Unlocking the full potential of end-to-end bioprocessing capabilities.
"With the growing demand for scalable and flexible bioprocessing solutions, Culture Biosciences is positioned to lead the industry into the next era of innovation and deliver transformative solutions to our customers."
Chris Williams
CEO of Culture BiosciencesCulture is addressing the bottlenecks in bioprocess development and reducing scale-up complexity.
Culture’s bioreactors address key industry pain points by making bioprocess development faster, cheaper, and more efficient.
Synthesis Collaboration
Synthesis has worked closely with Culture since their Series B round in 2021.
Why we backed them:
Our vision of a sustainable food system does not consist of technologies or products in silos, but of multiple solutions working together to create the future of food. Culture Biosciences is one of the enablers driving meaningful, system-level change in bioprocessing for food and beyond.
How Synthesis engaged:
Synthesis first invested in Culture’s Series B in 2021. Since then, we’ve worked closely with the team through its strategic expansion from a service-based model to also selling its own bioreactor hardware and cloud software. We leveraged our network to facilitate discussions with life-sciences giants, and doubled down with follow-on funding to help Culture realise its vision.
